Peter Valent Selected Research

CD2 Antigens

1/2006	Expression of cell surface antigens on mast cells: mast cell phenotyping.
7/2003	Morphologic and immunophenotypic properties of neoplastic cells in a case of mast cell sarcoma.
2/2002	Histopathological and immunohistochemical aspects of mastocytosis.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Peter Valent Research Topics

Disease

86	Neoplasms (Cancer) 10/2022 - 04/2002
59	Systemic Mastocytosis 01/2022 - 01/2002
51	BCR-ABL Positive Chronic Myelogenous Leukemia (Chronic Myelogenous Leukemia) 09/2022 - 11/2002
50	Leukemia 01/2022 - 11/2002
49	Hypersensitivity (Allergy) 01/2022 - 05/2002
43	Mastocytosis 01/2022 - 02/2002
34	Acute Myeloid Leukemia (Acute Myelogenous Leukemia) 01/2021 - 12/2002
14	Anaphylaxis (Anaphylactic Shock) 01/2022 - 05/2007
14	Inflammation (Inflammations) 11/2020 - 07/2002
14	Seasonal Allergic Rhinitis (Hay Fever) 09/2016 - 01/2002
13	Myelodysplastic Syndromes (Myelodysplastic Syndrome) 10/2020 - 02/2006
9	Hematologic Neoplasms (Hematological Malignancy) 01/2022 - 04/2004
9	Mast-Cell Leukemia (Leukemia, Mast Cell) 01/2021 - 01/2002
9	Disease Progression 01/2020 - 04/2004
9	Lymphoma (Lymphomas) 01/2018 - 01/2008
8	Eosinophilia 01/2022 - 09/2006
8	Chronic Myelomonocytic Leukemia (Leukemia, Chronic Myelomonocytic) 05/2021 - 11/2002
7	Mast Cell Activation Disorders (Mast-Cell Disease) 01/2022 - 10/2005
7	Mastocytoma 03/2018 - 02/2007
6	Hereditary alpha-tryptasemia syndrome 01/2022 - 11/2020
6	Primary Myelofibrosis (Myelosclerosis) 07/2020 - 06/2002
6	Philadelphia Chromosome 09/2017 - 12/2010
6	Pdgfra-Associated Chronic Eosinophilic Leukemia 10/2014 - 09/2006
5	Melanoma (Melanoma, Malignant) 01/2021 - 04/2002
5	Infections 10/2017 - 02/2006
5	Aplastic Anemia (Anemia, Hypoplastic) 06/2017 - 03/2002
5	Asthma (Bronchial Asthma) 03/2017 - 05/2004
4	Blast Crisis (Blast Phase) 09/2022 - 04/2004
4	Mast Cell Activation Syndrome 01/2022 - 01/2019
4	B-Cell Lymphoma (Lymphoma, B Cell) 01/2020 - 01/2017
4	Ovarian Neoplasms (Ovarian Cancer) 05/2018 - 09/2011
4	Atopic Dermatitis (Atopic Eczema) 02/2016 - 07/2005
4	Precursor Cell Lymphoblastic Leukemia-Lymphoma (Acute Lymphoblastic Leukemia) 03/2014 - 01/2005
4	Myeloid Leukemia (Leukemia, Myelocytic) 05/2011 - 11/2002
3	Polycythemia Vera 01/2022 - 02/2006
3	Chromosome Aberrations (Chromosome Abnormalities) 01/2021 - 05/2012
3	Anemia 11/2019 - 09/2008
3	Thrombocytopenia (Thrombopenia) 11/2019 - 04/2017
3	Pulmonary Hypertension 01/2017 - 11/2008
3	Multiple Myeloma 12/2016 - 04/2004
3	Hepatitis B 09/2016 - 06/2011
3	Autoimmune Hemolytic Anemia (Cold Agglutinin Disease) 04/2016 - 01/2008

Drug/Important Bio-Agent (IBA)

41	Immunoglobulin E (IgE)IBA 01/2022 - 05/2002
41	AllergensIBA 02/2021 - 01/2002
39	Tryptases (Tryptase)IBA 01/2022 - 06/2002
28	Imatinib Mesylate (Gleevec)FDA Link 01/2016 - 07/2004
22	Pharmaceutical PreparationsIBA 01/2022 - 01/2007
21	Tyrosine Kinase InhibitorsIBA 09/2022 - 10/2011
17	CytokinesIBA 01/2022 - 02/2002
17	VaccinesIBA 01/2021 - 01/2002
17	Proteins (Proteins, Gene)FDA Link 01/2021 - 11/2002
16	Biological ProductsIBA 01/2022 - 03/2005
15	AntibodiesIBA 01/2022 - 02/2002
13	Phosphotransferases (Kinase)IBA 10/2020 - 08/2007
12	Oncogene Proteins (Oncogene Protein)IBA 01/2020 - 12/2007
12	Immunoglobulin G (IgG)IBA 12/2019 - 08/2002
10	midostaurinIBA 01/2022 - 04/2007
10	Dasatinib (BMS 354825)FDA Link 01/2017 - 08/2007
10	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 04/2010 - 02/2002
9	nilotinib FDA Link 01/2018 - 10/2007
8	ponatinibIBA 01/2021 - 09/2013
8	AntigensIBA 10/2020 - 09/2002
7	Peptides (Polypeptides)IBA 09/2016 - 05/2009
6	Cytarabine (Cytosar-U)FDA LinkGeneric 12/2021 - 06/2004
6	Codon (Codons)IBA 06/2019 - 01/2002
5	Arthropod VenomsIBA 01/2022 - 10/2002
5	Transcription Factors (Transcription Factor)IBA 12/2021 - 10/2014
5	Biomarkers (Surrogate Marker)IBA 03/2021 - 12/2002
5	Messenger RNA (mRNA)IBA 03/2014 - 11/2002
5	bcr-abl Fusion ProteinsIBA 01/2013 - 12/2007
4	Core Binding Factors (Core-Binding Factor)IBA 01/2021 - 01/2018
4	L-Lactate Dehydrogenase (Lactate Dehydrogenase)IBA 01/2021 - 01/2008
4	ParaffinIBA 01/2020 - 04/2004
4	ruxolitinibIBA 01/2020 - 12/2016
4	Indicators and Reagents (Reagents)IBA 01/2018 - 10/2003
4	P-2 (P 2)IBA 05/2015 - 08/2002
4	Heme Oxygenase-1IBA 03/2014 - 05/2004
4	Surface Antigens (Surface Antigen)IBA 01/2014 - 01/2003
4	EpitopesIBA 04/2013 - 05/2004
4	Complement System Proteins (Complement)IBA 10/2010 - 07/2002
4	Peptide Hydrolases (Proteases)FDA Link 01/2008 - 07/2002
3	Poly(ADP-ribose) Polymerase InhibitorsIBA 10/2021 - 12/2018
3	Phosphatidylinositol 3-Kinases (PI 3 Kinase)IBA 01/2021 - 02/2007
3	DNA (Deoxyribonucleic Acid)IBA 10/2020 - 11/2002
3	Intercellular Signaling Peptides and Proteins (Growth Factors)IBA 08/2020 - 02/2007
3	Protein Isoforms (Isoforms)IBA 01/2019 - 04/2002
3	Histamine (Histamine Dihydrochloride)FDA Link 01/2019 - 04/2008
3	Antineoplastic Agents (Antineoplastics)IBA 12/2018 - 03/2003
3	dactolisibIBA 09/2017 - 09/2011
3	Membrane Proteins (Integral Membrane Proteins)IBA 09/2016 - 05/2009
3	Protein-Tyrosine Kinases (Tyrosine Kinase)IBA 01/2016 - 05/2012

Therapy/Procedure

79	Therapeutics 10/2022 - 05/2002
19	Immunotherapy 11/2020 - 01/2002
12	Drug Therapy (Chemotherapy) 01/2021 - 07/2004
8	Hematopoietic Stem Cell Transplantation 01/2017 - 12/2010
7	Precision Medicine 01/2022 - 12/2016
5	Stem Cell Transplantation 01/2021 - 07/2004
4	Transplantation 01/2018 - 01/2005
3	Critical Care (Surgical Intensive Care) 01/2019 - 02/2011
3	Cell Transplantation 01/2018 - 01/2016